Publications by authors named "Josef Brueggen"

12Publications

Effects of somatostatin analogs on glucose homeostasis in rats.

Authors:
Herbert A Schmid Josef Brueggen

J Endocrinol 2012 Jan 10;212(1):49-60. Epub 2011 Oct 10.

Novartis Pharma AG, Novartis Institutes for Biomedical Research, Oncology, CH-4057 Basel, Switzerland.

View Article and Find Full Text PDF
January 2012

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Authors:
Vito Guagnano Pascal Furet Carsten Spanka Vincent Bordas Mickaël Le Douget Christelle Stamm Josef Brueggen Michael R Jensen Christian Schnell Herbert Schmid Markus Wartmann Joerg Berghausen Peter Drueckes Alfred Zimmerlin Dirksen Bussiere Jeremy Murray Diana Graus Porta

J Med Chem 2011 Oct 21;54(20):7066-83. Epub 2011 Sep 21.

Novartis Institute for BioMedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
October 2011

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Authors:
Fabienne Baffert Catherine H Régnier Alain De Pover Carole Pissot-Soldermann Gisele A Tavares Francesca Blasco Josef Brueggen Patrick Chène Peter Drueckes Dirk Erdmann Pascal Furet Marc Gerspacher Marc Lang David Ledieu Lynda Nolan Stephan Ruetz Joerg Trappe Eric Vangrevelinghe Markus Wartmann Lorenza Wyder Francesco Hofmann Thomas Radimerski

Mol Cancer Ther 2010 Jul 29;9(7):1945-55. Epub 2010 Jun 29.

Disease Area Oncology, Novartis Institutes for BioMedical Research, 4057 Basel, Switzerland.

View Article and Find Full Text PDF
July 2010

Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.

Authors:
Terence O'Reilly Heidi A Lane Jeanette M Wood Christian Schnell Amanda Littlewood-Evans Josef Brueggen Paul M J McSheehy

Cancer Chemother Pharmacol 2011 Jan 30;67(1):193-200. Epub 2010 May 30.

Novartis Institutes for Biomedical Research, Oncology Research, 4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2011

Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800.

Authors:
Andrew J Massey Joseph Schoepfer Paul A Brough Josef Brueggen Patrick Chène Martin J Drysdale Ulrike Pfaar Thomas Radimerski Stephan Ruetz Alain Schweitzer Mike Wood Carlos Garcia-Echeverria Michael Rugaard Jensen

Mol Cancer Ther 2010 Apr 6;9(4):906-19. Epub 2010 Apr 6.

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Klybeckstrasse 141, WKL-125.2.42, CH-4057 Basel, Switzerland.

View Article and Find Full Text PDF
April 2010

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Authors:
Sauveur-Michel Maira Frédéric Stauffer Josef Brueggen Pascal Furet Christian Schnell Christine Fritsch Saskia Brachmann Patrick Chène Alain De Pover Kevin Schoemaker Doriano Fabbro Daniela Gabriel Marjo Simonen Leon Murphy Peter Finan William Sellers Carlos García-Echeverría

Mol Cancer Ther 2008 Jul 7;7(7):1851-63. Epub 2008 Jul 7.

Oncology Disease Area, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2008

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.

Authors:
Michael Rugaard Jensen Joseph Schoepfer Thomas Radimerski Andrew Massey Chantale T Guy Josef Brueggen Cornelia Quadt Alan Buckler Robert Cozens Martin J Drysdale Carlos Garcia-Echeverria Patrick Chène

Breast Cancer Res 2008 22;10(2):R33. Epub 2008 Apr 22.

Novartis Institutes for BioMedical Research, Oncology Research, Klybeckstrasse 141, CH-4057 Basel, Switzerland.

View Article and Find Full Text PDF
July 2008

Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.

Authors:
Lucy Lee Sunil Sharma Bruno Morgan Peter Allegrini Christian Schnell Josef Brueggen Robert Cozens Mark Horsfield Clemens Guenther Will P Steward Joachim Drevs David Lebwohl Jeanette Wood Paul M J McSheehy

Cancer Chemother Pharmacol 2006 Jun 20;57(6):761-71. Epub 2005 Sep 20.

Translational and Clinical Development, Oncology Business Unit, Novartis Pharmaceutical, One Health Plaza Bldg 105, East Hanover, NJ 07936, USA.

View Article and Find Full Text PDF
June 2006

Antitumor activity of imatinib mesylate in neuroblastoma xenografts.

Authors:
Daniela Meco Anna Riccardi Tiziana Servidei Josef Brueggen Marco Gessi Riccardo Riccardi Carlo Dominici

Cancer Lett 2005 Oct;228(1-2):211-9

Department of Pediatrics, Catholic University, Rome, Italy.

View Article and Find Full Text PDF
October 2005

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

Authors:
Markus Rudin Paul M J McSheehy Peter R Allegrini Martin Rausch Diana Baumann Mike Becquet Karin Brecht Josef Brueggen Stephane Ferretti Fabienne Schaeffer Christian Schnell Jeanette Wood

NMR Biomed 2005 Aug;18(5):308-21

Discovery Technology, Novartis Pharma AG, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
August 2005

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Authors:
Peter Traxler Peter R Allegrini Ralf Brandt Josef Brueggen Robert Cozens Doriano Fabbro Konstantina Grosios Heidi A Lane Paul McSheehy Jürgen Mestan Thomas Meyer Careen Tang Markus Wartmann Jeanette Wood Giorgio Caravatti

Cancer Res 2004 Jul;64(14):4931-41

Oncology Research, Novartis Institutes for Biomedical Research, Klybeckstrasse, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

Authors:
Carlos García-Echeverría Mark A Pearson Andreas Marti Thomas Meyer Juergen Mestan Johann Zimmermann Jiaping Gao Josef Brueggen Hans-Georg Capraro Robert Cozens Dean B Evans Doriano Fabbro Pascal Furet Diana Graus Porta Janis Liebetanz Georg Martiny-Baron Stephan Ruetz Francesco Hofmann

Cancer Cell 2004 Mar;5(3):231-9

Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2004